Experimental immune cell therapy targets tough leukemia

NCT ID NCT05712278

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested an off-the-shelf natural killer (NK) cell therapy called SAR445419 in adults with acute myeloid leukemia that returned or didn't respond to treatment. Participants received chemotherapy followed by the NK cells to see if it was safe and could help control the disease. The study was terminated early after enrolling only 7 people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloblastic leukemia with maturation acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKAEMIA

Contacts and locations

Locations

Albert Einstein College of Medicine Site Number : 8400001

The Bronx, New York, 10461, United States
University of Nebraska Medical Center Site Number : 8400003

Omaha, Nebraska, 68198-2168, United States
~MD Anderson Cancer Center Site Number : 8400002

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.